Secukinumab
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Discoid Lupus Erythematosus
Conditions
Discoid Lupus Erythematosus
Trial Timeline
Sep 1, 2019 → Jun 30, 2021
NCT ID
NCT03866317About Secukinumab
Secukinumab is a phase 2 stage product being developed by Novartis for Discoid Lupus Erythematosus. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03866317. Target conditions include Discoid Lupus Erythematosus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05583604 | Pre-clinical | Active |
| NCT07243782 | Pre-clinical | Recruiting |
| NCT06751238 | Phase 1 | Recruiting |
| NCT06905288 | Pre-clinical | Recruiting |
| NCT06331312 | Phase 3 | Recruiting |
| NCT06130540 | Phase 1 | Completed |
| NCT05569174 | Phase 3 | Completed |
| NCT05232864 | Phase 3 | Terminated |
| NCT05206591 | Phase 3 | Withdrawn |
| NCT04894890 | Pre-clinical | Completed |
| NCT04717466 | Approved | Completed |
| NCT05677542 | Pre-clinical | Completed |
| NCT05513014 | Pre-clinical | Completed |
| NCT05320159 | Pre-clinical | Completed |
| NCT05650060 | Pre-clinical | Completed |
| NCT03866317 | Phase 2 | Withdrawn |
| NCT03769168 | Phase 3 | Completed |
| NCT03791060 | Phase 2 | Terminated |
| NCT03440736 | Approved | Completed |
| NCT03307447 | Approved | UNKNOWN |
Competing Products
7 competing products in Discoid Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Daxdilimab | Amgen | Phase 2 | 51 |
| Tofacitinib citrate | Pfizer | Phase 1 | 32 |
| Etanercept | Pfizer | Phase 2 | 51 |
| Deucravacitinib + Placebo | Bristol Myers Squibb | Phase 2 | 51 |
| Belimumab 1 mg/kg + Belimumab 10 mg/kg | GSK plc | Pre-clinical | 22 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| R932333 + Placebo | Rigel Pharmaceuticals | Phase 2 | 44 |